 Connection
Scot Sedlacek to Breast Neoplasms
This is a "connection" page, showing publications Scot Sedlacek has written about Breast Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.905 |
|
|
|
-
Sedlacek SM, Playdon MC, Wolfe P, McGinley JN, Wisthoff MR, Daeninck EA, Jiang W, Zhu Z, Thompson HJ. Effect of a low fat versus a low carbohydrate weight loss dietary intervention on biomarkers of long term survival in breast cancer patients ('CHOICE'): study protocol. BMC Cancer. 2011 Jul 06; 11:287.
Score: 0.138
-
Jones VE, McIntyre KJ, Paul D, Wilks ST, Ondreyco SM, Sedlacek S, Melnyk A, Oommen SP, Wang Y, Peck SR, O'Shaughnessy JA. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. Oncologist. 2019 09; 24(9):1153-1158.
Score: 0.059
-
Leonard CE, Philpott P, Shapiro H, Corkill M, Gonzales C, Ponce J, Howell K, Aarestad N, Sedlacek SM. Clinical observations of axillary involvement for tubular, lobular, and ductal carcinomas of the breast. J Surg Oncol. 1999 Jan; 70(1):13-20.
Score: 0.058
-
Leonard CE, Wood ME, Zhen B, Rankin J, Waitz DA, Norton L, Howell K, Sedlacek S. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control? J Clin Oncol. 1995 Dec; 13(12):2906-15.
Score: 0.047
-
Thompson HJ, Sedlacek SM, Wolfe P, Paul D, Lakoski SG, Playdon MC, McGinley JN, Matthews SB. Impact of Weight Loss on Plasma Leptin and Adiponectin in Overweight-to-Obese Post Menopausal Breast Cancer Survivors. Nutrients. 2015 Jun 26; 7(7):5156-76.
Score: 0.046
-
O'Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, Pippen J, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Brownstein C, Hoersch S, Blum JL, Jones S. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin Cancer Res. 2015 Oct 01; 21(19):4305-11.
Score: 0.045
-
Thompson HJ, Sedlacek SM, Playdon MC, Wolfe P, McGinley JN, Paul D, Lakoski SG. Weight loss interventions for breast cancer survivors: impact of dietary pattern. PLoS One. 2015; 10(5):e0127366.
Score: 0.045
-
Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013 Oct; 14(11):1121-1128.
Score: 0.040
-
Sedlacek SM. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine. Oncology. 1993 Apr; 50 Suppl 1:16-21.
Score: 0.039
-
Thompson HJ, Sedlacek SM, Paul D, Wolfe P, McGinley JN, Playdon MC, Daeninck EA, Bartels SN, Wisthoff MR. Effect of dietary patterns differing in carbohydrate and fat content on blood lipid and glucose profiles based on weight-loss success of breast-cancer survivors. Breast Cancer Res. 2012 Jan 06; 14(1):R1.
Score: 0.036
-
Leonard CE, Johnson T, Tallhamer M, Howell K, Kercher J, Kaske T, Barke L, Sedlacek S, Hobart T, Carter DL. Accelerated partial breast intensity-modulated radiotherapy in women who have prior breast augmentation. Clin Breast Cancer. 2011 Jun; 11(3):184-90.
Score: 0.034
-
Marcus AC, Garrett KM, Cella D, Wenzel L, Brady MJ, Fairclough D, Pate-Willig M, Barnes D, Emsbo SP, Kluhsman BC, Crane L, Sedlacek S, Flynn PJ. Can telephone counseling post-treatment improve psychosocial outcomes among early stage breast cancer survivors? Psychooncology. 2010 Sep; 19(9):923-32.
Score: 0.033
-
Sedlacek SM. Salvage therapy for metastatic disease. Semin Oncol. 1990 Aug; 17(4 Suppl 7):45-9.
Score: 0.032
-
Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010 Jun 20; 28(18):2958-65.
Score: 0.032
-
Leonard CE, Tallhamer M, Johnson T, Hunter K, Howell K, Kercher J, Widener J, Kaske T, Paul D, Sedlacek S, Carter DL. Clinical experience with image-guided radiotherapy in an accelerated partial breast intensity-modulated radiotherapy protocol. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):528-34.
Score: 0.030
-
Osborne CR, Duncan A, Sedlacek S, Paul D, Holmes F, Vukelja S, Kasper M, Wilks S, Schneider A, McGee R, Meyer WG, O'Shaughnessy JA. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat. 2009 Aug; 116(3):521-7.
Score: 0.029
-
Reeder R, Carter DL, Howell K, Henkenberns P, Tallhamer M, Johnson T, Kercher J, Widner J, Kaske T, Paul D, Sedlacek S, Leonard CE. Predictors for clinical outcomes after accelerated partial breast intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2009 May 01; 74(1):92-7.
Score: 0.028
-
Sedlacek SM. An overview of megestrol acetate for the treatment of advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):3-13.
Score: 0.028
-
Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 01; 23(16):3686-96.
Score: 0.023
-
Sedlacek SM, Horwitz KB. The role of progestins and progesterone receptors in the treatment of breast cancer. Steroids. 1984 Dec; 44(6):467-84.
Score: 0.022
-
Leonard CE, Sedlacek S, Shapiro H, Hey D, Liang X, Howell K, Vernon B, Ponce J, Smith L. Lumpectomy and breast radiotherapy in breast cancer patients with a family history of breast cancer, ovarian cancer, or both. Breast J. 2002 May-Jun; 8(3):154-61.
Score: 0.018
-
Marcus AC, Ahnen D, Cutter G, Calonge N, Russell S, Sedlacek SM, Wood M, Manchester D, Fox L, McCaskill-Stevens W, Fairclough D, Hines S, Wenzel L, Osborn K. Promoting cancer screening among the first-degree relatives of breast and colorectal cancer patients: the design of two randomized trials. Prev Med. 1999 Mar; 28(3):229-42.
Score: 0.015
-
Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996 May; 13(1):123-5.
Score: 0.012
-
Bedell MB, Wood ME, Lezotte DC, Sedlacek SM, Orleans MM. Delay in diagnosis and treatment of breast cancer: implications for education. J Cancer Educ. 1995; 10(4):223-8.
Score: 0.011
-
Horwitz KB, Wei LL, Sedlacek SM, d'Arville CN. Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog Horm Res. 1985; 41:249-316.
Score: 0.006
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|